XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others.
Código de la empresaXOMA
Nombre de la empresaXOMA Royalty Corp
Fecha de salida a bolsaJun 06, 1986
Fundada en2011
Director ejecutivoMr. Owen P. Hughes, Jr.
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 06
Dirección2200 Powell Street
CiudadEMERYVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94608
Teléfono15102047239
Sitio Webhttps://www.xoma.com/
Código de la empresaXOMA
Fecha de salida a bolsaJun 06, 1986
Fundada en2011
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos